Poster Presentation The Pancreas Summit 2025

Initial perceptions of Australian clinicians participating in the SCANPatient clinical trial of synoptic reporting of CT scans to assess pancreatic cancer (#6)

Lin Li 1 , Ariadna Recasens 1 , Liane Ioannou 1 , Samantha J Ellis 2 , John R Zalcberg 1 , Charles Pilgrim 2
  1. Monash University, Melbourne, VIC, Australia
  2. Alfred Health, Melbourne, VIC, Australia

Purpose: To report initial perceptions and user experience of synoptic reporting of CT scans in assessing cancer of the pancreas among radiologists and hepatobiliary (HPB) surgeons involved in a multi-centre clinical trial.

Methods: A Clinician Satisfaction Survey was sent to participating clinicians involved in the MRFF-funded SCANPatient trial which includes 33 participating hospitals across Australia (1). The survey was administered online from December 2023 - April 2024 prior to any participating site being randomised to synoptic reporting. The survey included questions about clinicians’ speciality, previous experience using synoptic/structured CT scan reports, perceptions/use and satisfaction with the level of anatomical details discussed/documented in their multidisciplinary team meetings, and opinions about the potential usefulness and effectiveness of synoptic/structured reporting in determining the resectability status of pancreatic tumours. Descriptive analyses were conducted to gauge clinicians’ perceptions and experiences.

Results: Twenty three clinicians anonymously completed the survey (from 67 who were sent the link, with a 34% response rate). The respondents were 10 radiologists (including 5 abdominal imaging specialists, 4 general radiologists and 1 other specialist) and 13 surgeons (12 HPB surgeons and 1 surgical oncologist). Thirteen respondents (57%) had 10+ years of specialty practice. The most commonly used/cited resectability classification systems were those of the National Comprehensive Cancer Network (7/23), followed by the International Consensus 2017 (2) (6/23). On a scale of 1-5, mean satisfaction score and standard deviation for “anatomical detail discussed” in the MDM for CT scans were 3.57 ± 0.66 among all respondents (3.69 ± 0.75 among surgeons and 3.40 ± 0.52 among radiologists); 3.15 ± 0.69 for “anatomical detail documented”; and 3.23 ± 0.60 for “ease of determining resectability”. Nine radiologists had used synoptic reporting in any tumour type. Half of the radiologists had used a template report for non-metastatic PDAC. Only 3 radiologists routinely included a resectability status in their reporting of PDAC. Nineteen out of 23 clinicians believed synoptic/structured reporting of pancreas cancer CT scans will be useful.  

Conclusion: Initial findings indicate strong clinician support for synoptic CT reporting in assessing PDAC, highlighting its potential to improve communication of anatomical details and determination of tumour resectability.

  1. 1. Li L, Kasza J, Recasens A, et al. SCANPatient: study protocol for a multi-centre, batched, stepped wedge, comparative effectiveness, randomised clinical trial of synoptic reporting of computerised tomography (CT) scans assessing cancers of the pancreas. Trials. 2024;25(1):388.
  2. 2. Isaji S, Mizuno S, Windsor JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18(1):2-11.